Consultancy
Patient-Focused Drug Development
Real patient experience, embedded at every stage
Overview
Patient-Focused Drug Development (PFDD) is the discipline of building the patient's own experience of their condition — what matters to them, what they can tolerate, what a meaningful improvement looks like — systematically into a drug development programme, rather than treating it as a late-stage communications exercise. For rare disease in particular, where the patient population is small and every voice carries proportionally more weight, this discipline is not optional: regulators now expect to see it.
What we do
- Patient experience data — systematic approaches to gather insight that meets regulatory standards, not just anecdote.
- PFDD meeting support — preparing for FDA Patient Listening Sessions and externally led PFDD meetings.
- Endpoint strategy — endpoints that capture the outcomes patients actually care about, not only what is easiest to measure.
- Benefit–risk assessment — patient preferences built into frameworks that regulators and payers recognise.
Where this creates value
The FDA's PFDD guidance series and the EMA's patient engagement framework both push in the same direction: development programmes that can show how patient input shaped endpoint selection and benefit-risk assessment move through review with fewer open questions. In small rare disease populations, that evidence is also often the clearest way to demonstrate that a therapy addresses something patients genuinely experience as burdensome — which matters as much to payers assessing value as it does to regulators assessing efficacy.
Why CortexBio
CortexBio brings the same rare disease development discipline to patient engagement as to every other part of the programme — grounded in 30 years of experience across Genzyme, Astellas and Abbott, where Dima Martini-Drew, MD, worked directly with rare disease patient communities on registry design. Patient experience data is treated as evidence to be gathered rigorously, not a box to tick before submission.
Who this is for
Sponsors preparing for an FDA or EMA interaction where patient experience evidence will be expected, teams designing a rare disease trial who want endpoints that hold up to scrutiny from both regulators and the patient community, and companies building a benefit-risk case ahead of submission or payer conversations. This work sits closest to CortexBio's advocacy and clinical development readiness services, and is often most effective run alongside one or both.
Frequently asked questions
What is patient-focused drug development?
A structured approach to gathering and using patients' own experience of their condition — what matters most to them and what a meaningful treatment benefit looks like — to shape endpoint selection, trial design and benefit-risk assessment, in line with FDA and EMA guidance.
Why does PFDD matter more in rare disease?
With small, often geographically dispersed patient populations, every patient's input carries more statistical and clinical weight, and regulators increasingly expect to see how that input shaped the programme rather than being gathered as an afterthought.
What is a PFDD meeting?
A structured session — either an FDA Patient Listening Session or an externally led meeting — where patients and caregivers describe their condition and treatment priorities directly to a sponsor or regulator, generating evidence that feeds into endpoint and benefit-risk strategy.
How does patient experience data affect benefit-risk assessment?
It grounds the assessment in what patients themselves are willing to tolerate for a given level of benefit, producing a framework regulators and payers can weigh alongside clinical trial data rather than a generic risk tolerance assumption.
Does patient-focused drug development slow a programme down?
Done early, it tends to do the opposite — endpoints and trial design choices grounded in what patients actually value are less likely to be challenged late in review, and the evidence gathered often doubles as material for benefit-risk submissions and payer conversations that would otherwise need separate work.
What regulatory guidance governs patient-focused drug development?
In the US, the FDA's PFDD guidance series (issued under the 21st Century Cures Act framework) sets out how patient experience data should be collected and used. In the EU, the EMA's patient engagement framework covers similar ground. Both expect the process to be systematic and documented, not anecdotal — which is why CortexBio treats patient experience data collection as evidence generation, built to the same rigour as any other part of the clinical development plan.
How an engagement works
Work typically begins with mapping what patient experience evidence already exists for the condition — published literature, prior advocacy engagement, any existing natural history data — and identifying the gaps that matter for the specific development stage. Where new evidence is needed, CortexBio designs the collection approach (structured interviews, surveys, or a formal PFDD meeting) to meet the standard regulators expect, then works with the clinical team to translate findings into endpoint strategy and benefit-risk framing that can be defended at submission.
Because patient input should shape a programme rather than validate decisions already made, this work is most valuable when it starts alongside — not after — early clinical strategy.